Nancy Davidson
Affiliations: | Johns Hopkins University, Baltimore, MD |
Area:
Biochemistry, Molecular BiologyGoogle:
"Nancy Davidson"Mean distance: (not calculated yet)
Children
Sign in to add trainee| Julie L. Blum | grad student | 2006 | Johns Hopkins |
| Allison M. Pledgie | grad student | 2006 | Johns Hopkins |
| Abigail E. Witt | grad student | 2010 | Johns Hopkins |
| Talmesha A. Richards | grad student | 2012 | Johns Hopkins |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Yin J, Gu T, Chaudhry N, et al. (2024) Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications. Frontiers in Immunology. 14: 1325615 |
| Symonds LK, Davidson NE. (2023) Are we there yet? Optimal duration of endocrine therapy in women with postmenopausal early-stage hormone receptor-positive breast cancer. Journal of the National Cancer Institute |
| Garcia-Recio S, Hinoue T, Wheeler GL, et al. (2022) Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nature Cancer |
| Francis PA, Fleming GF, Láng I, et al. (2022) Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2201065 |
| Davidson NE. (2022) In It for the Long Haul: Long-Term Benefit With Adjuvant Endocrine Therapy for Premenopausal Women With Early-Stage Steroid Receptor-Positive Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2201465 |
| Giordano SH, Franzoi MAB, Temin S, et al. (2022) Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2200519 |
| Ramakrishna N, Anders CK, Lin NU, et al. (2022) Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2200520 |
| Manohar PM, Davidson NE. (2021) Updates in endocrine therapy for metastatic breast cancer. Cancer Biology & Medicine |
| Yung RL, Davidson NE. (2021) Optimal adjuvant endocrine therapy for breast cancer. The Lancet. Oncology. 22: 1357-1358 |
| Moy B, Rumble RB, Come SE, et al. (2021) Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2101374 |